Abstracts tagged "Granulomatosis with Polyangiitis (GPA)"

Abstract Number: 0725 • ACR Convergence 2023
Real-life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis
Sophie Nagle¹, Yann Nguyen², Xavier Puéchal³, Dimitri Titeca-Beauport⁴, Thomas Crépin⁵, Rafik Mesbah⁶, Idris Boudhabhay⁷, Gregory Pugnet⁸, Juliette Woessner⁹, Roderau Outh¹⁰, Céline Lebas¹¹, Antoine Néel¹², alexandre Karras¹³, Eric Hachulla¹¹, Benjamin Subran¹⁴, Philippe Kerschen¹⁵, Mathieu Gerfaud-Valentin¹⁶, Stéphane Vinzio¹⁷, Tiphaine Goulenok¹⁸, Raphael Borie¹⁹, Sébastien Humbert²⁰, Yurdagul Uzunhan²¹, Sarah Melboucy-Belkhir²², Jean-Baptiste Gouin²³, Mary-Jane Guerry²⁴ and Benjamin Terrier²⁵, ¹AP-HP Cochin Hospital, Paris, France, ²Department of Internal Medicine, Hôpital Beaujon, AP-HP, Clichy, France., Montmorency, France, ³National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, ⁴CHU Amiens, Amiens, France, ⁵Amiens University Hospital, Amiens, France, ⁶Boulogne Hospital (CH), Boulogne, France, ⁷Necker University Hospital, Paris, France, ⁸CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France, ⁹Avignon Hospital (CH), Avignon, France, ¹⁰Perpignan Hospital (CH), Perpignan, France, ¹¹Lille University Hospital, Lille, France, ¹²CHU Nantes, Nantes, France, ¹³HEGP - APHP, Paris, France, ¹⁴Croix Saint Simon Hospital, Paris, France, ¹⁵Department of Neurology, Luxembourg Hospital Center, Luxembourg City, Luxembourg, ¹⁶Lyon University Hospital, Lyon, France, ¹⁷Grenoble Hospital (CH), Grenoble, France, ¹⁸Assistance Publique Hopitaux de Paris, Paris, France, ¹⁹Bichat-Claude Bernard, Universite de Paris, Paris, France, ²⁰Besançon University Hospital, Besançon, France, ²¹AP-HP, Bobigny, France, ²²Saint Quentin Hospital, Saint-Quentin, France, ²³Vannes Hospital (CH Bretagne Atlantique), Vannes, France, ²⁴Valenciennes Hospital (CH), Valenciennes, France, ²⁵Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France
Background/Purpose: Glucocorticoids (GCs) in combination with rituximab (RTX) or cyclophosphamide are the cornerstone of treatment for patients with severe granulomatosis with polyangiitis (GPA) and microscopic…
Abstract Number: 0857 • ACR Convergence 2023
Change in Albuminuria in Patients with ANCA-Associated Vasculitis Treated with Avacopan
Duvuru Geetha¹, Frank Cortazar², alexandre Karras³, Annette Bruchfeld⁴, Huibin Yue⁵, Peter Merkel⁶ and David Jayne⁷, ¹Johns Hopkins University, Baltimore, MD, ²New York Nephrology, Watervliet, NY, ³HEGP - APHP, Paris, France, ⁴Karolinska Institutet, Stockholm, Sweden, ⁵Amgen, Inc., Thousand Oaks, CA, ⁶University of Pennsylvania, Philadelphia, PA, ⁷University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Urinary albumin:creatinine ratio (UACR) is an important biomarker of active glomerulonephritis, a common complication of antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV). In most glomerular…
Abstract Number: 1535 • ACR Convergence 2023
Epidemiology and Treatment Outcome of ANCA-associated Vasculitis in South Korea: A Nationwide, Population-based Cohort Study
Ji In Jung¹, Jun Won Park², Song Jihun³, Seulggie Choi², Sun Jae Park³, Sang Min Park² and Eun Young Lee⁴, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, ²Seoul National University Hospital, Seoul, South Korea, ³Seoul National University Graduate School, Seoul, South Korea, ⁴Seoul National University College of Medicine, Seoul, South Korea
Background/Purpose: Previous studies on AAV have shown that the epidemiology and clinical features of GPA and MPA differ among countries. Considering their high mortality and…
Abstract Number: 1071 • ACR Convergence 2022
Trimethoprim Sulfamethoxazole Use in Patients with Granulomatosis with Polyangiitis Treated with Rituximab
Arielle Mendel¹, Hassan Behlouli², Cristiano Moura², Evelyne Vinet¹, Jeffrey Curtis³ and Sasha Bernatsky², ¹McGill University Health Centre, Montréal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ³Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Trimethoprim sulfamethoxazole (TMP-SMX) prophylaxis is recommended during induction of ANCA-associated vasculitis (AAV) to prevent pneumocystis jirovecii pneumonia (PJP), and may also reduce the risk…
Abstract Number: 1072 • ACR Convergence 2022
Efficacy and Safety Assessment of a Rituximab Biosimilar in Patients with Granulomatosis with Polyangiitis (GPA)
Adil Vural¹, Komal Mushtaq¹, Chao Zhang¹, Mahmoud Alwakeel¹, Vickie Sayles¹, Kristine Duly², Carol Langford¹ and Rula Hajj-Ali³, ¹Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic, Fairview Park, OH, ³Cleveland Clinic, Hunting Valley, OH
Background/Purpose: A biosimilar is a medication that is highly similar to a biologic agent that is already approved by a regulatory organization. Considering the share…
Abstract Number: 1080 • ACR Convergence 2022
Performance of Risk Prediction Models for Relapse and Severe Infection at the End of 18-month Rituximab Maintenance Therapy in ANCA-associated Vasculitides: Data from the MAINRITSAN Trials
Florence Delestre¹, Pierre Charles², Loïc Guillevin³, Raphaël Porcher⁴ and Benjamin Terrier³, ¹cochin Hospital, Paris, France, ²Institut Mutualiste Montsouris, Paris, France, ³National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ⁴Université Paris Cité, Hôtel-Dieu, Paris, France
Background/Purpose: Long-term follow-up analysis of the three MAINRITSAN trials confirmed the efficacy of rituximab (RTX) in preventing relapses in ANCA-associated vasculitis (AAV), especially RTX administration…
Abstract Number: 1082 • ACR Convergence 2022
Outcomes of Methotrexate as an Initial Induction and Maintenance Regimen for Localized Granulomatosis with Polyangiitis: A Retrospective Review
Pratyusha Banik¹, Marcia Friedman², Daniela Ghetie³, Dongseok Choi⁴ and Margaret Brophy¹, ¹Oregon Health & Science University, Portland, OR, ²Oregon Health and Science University, Division of Arthritis and Rheumatic Diseases, Portland, OR, ³Oregon Health & Science University, Division of Arthritis and Rheumatic Diseases, Lake Oswego, OR, ⁴OHSU-PSU School of Public Health, Portland, OR
Background/Purpose: While there is established data regarding the induction and maintenance treatment of systemic or organ threatening granulomatosis with polyangiitis (GPA), there is limited data…
Abstract Number: 1084 • ACR Convergence 2022
Rituximab versus Cyclophosphamide for Induction Therapy in Granulomatosis with Polyangiitis: A Target Trial Emulation Study
Xavier Puéchal¹, Michele Iudici², Elodie Perrodeau³, bernard bonnotte⁴, Francois Lifermann⁵, Thomas Le Gallou⁶, Alexandre Karras⁷, Claire Blanchard-Delaunay⁸, Thomas Quéméneur⁹, Achille Aouba¹⁰, Olivier Aumaître¹¹, Vincent Cottin¹², Mohamed Hamidou¹³, Marc Ruivard¹¹, Pascal Cohen¹, Luc Mouthon¹, Loïc Guillevin¹, Philippe Ravaud³, Raphaël Porcher³ and Benjamin Terrier¹, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ²Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland, ³Université Paris Cité, Hôtel-Dieu, Paris, France, ⁴Centre Hospitalo-Universitaire de Dijon, Dijon, France, ⁵Dax Hospital, Dax, France, ⁶Rennes Sud University Hospital, Rennes, France, ⁷HEGP, Paris, France, ⁸Niort Hospital, Niort, France, ⁹Valenciennes Hospital, Valenciennes, France, ¹⁰Department of Internal Medicine, UR4650 PSIR, Normandie Univ, UNICAEN, CHU de Caen Normandie, Caen, France, ¹¹Clermont Ferrand University Hospital, Clermont-Ferrand, France, ¹²Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, ¹³Nantes University Hospital, Nantes, France
Background/Purpose: Randomized controlled trials showed rituximab (RTX)'s non-inferiority to cyclophosphamide (CYC) for induction therapy of ANCA-associated vasculitis and neither treatment was favoured in granulomatosis with…
Abstract Number: 1948 • ACR Convergence 2022
Clinical Characteristics and Outcomes of Pediatric ANCA-Associated Vasculitis Patients: Single-Center Inception Cohort
Hyun Ho Lee¹, Lauren Blazek² and Eveline Wu³, ¹The University of North Carolina Chapel Hill, Chapel Hill, NC, ²UNC Kidney Center, The University of North Carolina Chapel Hill, Chapel Hill, NC, ³University of North Carolina, Chapel Hill, NC
Background/Purpose: ANCA associated vasculitis (AAV) is a chronic autoimmune disorder characterized by ANCA production and small vessel inflammation and necrosis. ANCA autoantigen targets include myeloperoxidase…
Abstract Number: 0439 • ACR Convergence 2022
Clinical Characteristics of Patients with ANCA-Associated Vasculitis with and Without Alpha-1 Antitrypsin Deficiency Alleles
Lynn Fussner¹, David Cuthbertson², Peter Grayson³, David Jayne⁴, Carol McAlear⁵, Michael Walsh⁶, Katherine Siminovitch⁷, Ulrich Specks⁸ and Peter Merkel⁹, ¹The Ohio State University, Columbus, OH, ²University of South Florida, Tampa, FL, ³National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁴University of Cambridge, Cambridge, United Kingdom, ⁵Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ⁶McMaster University, Hamilton, ON, Canada, ⁷University of Toronto, Toronto, ON, Canada, ⁸Mayo Clinic, Rochester, MN, ⁹University of Pennsylvania, Philadelphia, PA
Background/Purpose: There are multiple reasons to suspect that alpha-1 antitrypsin (A1AT) genotype impacts disease characteristics in ANCA-associated vasculitis (AAV). A1AT serves as the predominant endogenous…
Abstract Number: 0442 • ACR Convergence 2022
Induction Therapy Patterns for Severe ANCA-associated Vasculitis Differ Based on Physician Specialty, Expertise, and Practice Setting: An International Survey
Lilian Xu¹, Faten Aqeel¹, Ojaswi Tomar², Tingting Li² and Duvuru Geetha¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Washington University in St. Louis School of Medicine, St. Louis, MO
Background/Purpose: Therapies for ANCA-associated vasculitis (AAV) have evolved over the last 3 decades. In light of new data on plasma exchange (PLEX) and glucocorticoid (GC)…
Abstract Number: 0453 • ACR Convergence 2022
Validation of the 2022 – American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria in Patients with ANCA Associated Vasculitis
Aman Sharma¹, Prateek Deo¹, Shankar Naidu², Joydeep Samanta³, Sakshi Mittal³, Kusum Sharma³, Ritambhra Nada³, Varun Dhir⁴, sanjay jain² and Ranjana Minz², ¹PGIMER, Chandigarh, India, Chandigarh, India, ²Postgraduate Institute of Medical Education and Research, Chandigarh, India, ³PGIMER, Chandigarh, India, ⁴PGIMER, CHD, INDIA, Chandigarh, India
Background/Purpose: The purpose of this study was to validate the recently published 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for…
Abstract Number: 0454 • ACR Convergence 2022
Advantages and Disadvantages in Applying 2022 ACR/EULAR Classification Criteria to Conventionally Diagnosed Japanese GPA Patients
Ryo Kuwata¹, Yuko Shirota², Tsuyoshi Shirai³, Hiroyuki Yamashita¹, Hiroko Sato³, Tomoki Takeda², Yumiko Oka², Takao Kodera⁴, Hiroshi Kaneko¹, Junichi Kameoka⁵, Hiroshi Fujii³ and Tomonori Ishii⁶, ¹Division of Rheumatic diseases, National Center for Global Health and Medicine, Tokyo, Japan, ²Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan, ³Department of Rheumatology, Tohoku University Hospital, Sendai, Japan, ⁴Department of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan, ⁵Divison of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan, ⁶Clinical Research, Innovation and Education Center, Tohoku University Hospital, Sendai, Japan
Background/Purpose: The Chapel Hill Consensus Conference and the European Medicines Agency algorithm were commonly used to diagnose patients with granulomatosis with polyangiitis (GPA) 1）. Recently…
Abstract Number: 0455 • ACR Convergence 2022
Performance of 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria in Turkish Vasculitis Patients
Ummugulsum Gazel¹, Sevinc Can Sandikci², Ahmet Omma³, Sinem Burcu Kocaer⁴, Fatoş Onen⁵, Onay Gercik⁶, Servet Akar⁷, Kerem Abacar⁸, Ebru Asicioglu⁹, Serhan Tuglular⁹, Fatma Alibaz-Oner⁸ and Haner Direskeneli¹⁰, ¹University of Ottawa, Rheumatology, Ottawa, Canada, Ottawa, ON, Canada, ²Ankara Numune Education and Research Hospital, Rheumatology, Ankara, Turkey, ³Ankara Numune Education and Research Hospital, Rheumatology, Ankara, Turkey, Istanbul, Turkey, ⁴Dokuz Eylul University, Faculty of Medicine, Rheumatology, Izmir, Turkey, ⁵Dokuz Eylul University, Faculty of Medicine, Rheumatology, İzmir, Turkey, ⁶Izmir Tepecik Research Hospital, Izmir, Turkey, ⁷Izmir Katip Celebi University School of Medicine, Izmir, Turkey, ⁸Marmara University, Rheumatology, Istanbul, Turkey, ⁹Marmara University, Faculty of Medicine, Nephrology, Istanbul, Turkey, ¹⁰Marmara University, Rheumatology, Istanbul, Istanbul, Turkey
Background/Purpose: The American College of Rheumatology (ACR)-1990 criteria is the most used method for the classification of ANCA Associated Vasculitis (AAV). However, with ACR-1990 criteria,…
Abstract Number: 0457 • ACR Convergence 2022
A Systematic Literature Review Informing the 2022 Update of the EULAR Recommendations for the Management of ANCA-associated Vasculitis
Jan Schirmer¹, Beatriz Sanchez-Alamo², Sara Monti³, Bernhard Hellmich⁴, David Jayne⁵ and Gunnar Tomasson⁶, ¹University Medical Center Schleswig-Holstein, Kiel, Germany, ²Lund University, Skåne University Hospital, Lund, Sweden, ³Rheumatology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy, ⁴Medius Kliniken, University of Tübingen, Kirchheim Teck, Germany, ⁵University of Cambridge, Cambridge, United Kingdom, ⁶Centre for Rheumatology Research, University Hospital Reykjavik, Reykjavik, Iceland
Background/Purpose: Since the publication of the 2016 European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of ANCA-associated vasculitis (AAV), the publication of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].